title: A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy.
abstract: HIV-infected patients on antiretroviral therapy frequently develop changes in body fat distribution and disturbances in glucose metabolism, associated with reduced adiponectin levels. Because adiponectin, principally the high-molecular-weight (HMW) form, has insulin-sensitizing properties, we investigated the effects of an increase in adiponectin on glucose metabolism in HIV-lipodystrophy. In this randomized, double-blind, placebo-controlled trial, we included HIV-1-infected patients with severe lipoatrophy, with an undetectable viral load and who had received neither protease inhibitors nor stavudine for ≥6 mo. Patients were randomized to rosiglitazone [8 mg daily (n = 8)] to increase adiponectin levels or placebo (n = 5) for 16 wk. Peripheral glucose disposal, glucose production, and lipolysis were measured after an overnight fast and during a hyperinsulinemic-euglycemic clamp using stable isotopes. Body composition was assessed by computed tomography and dual-energy X-ray absorptiometry. Although body fat distribution was unaffected, rosiglitazone increased total plasma adiponectin levels by 107% (P < 0.02) and the ratio of HMW to total adiponectin by 73% (P < 0.001). In the placebo group, neither total adiponectin levels (P = 0.62) nor the ratio of HMW to total adiponectin changed (P = 0.94). The marked increase in adiponectin induced by rosiglitazone was not associated with significant changes in basal endogenous glucose production (P = 0.90), basal lipolysis (P = 0.90), insulin-mediated suppression of glucose production (P = 0.17) and lipolysis (P = 0.54) nor with changes in peripheral glucose disposal (P = 0.13). Acknowledging the limited statistical power of our small study, these findings, if confirmed by larger studies, could question the importance of adiponectin in regulating glucose metabolism in HIV-lipodystrophy.
authors.affiliation: Dept. of Endocrinology and Metabolism, Academic Medical Center, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands. r.blumer@amc.uva.nl
authors.forename: Regje M E
authors.initials: RM
authors.lastname: Blümer
authors.forename: Marc
authors.initials: M
authors.lastname: van der Valk
authors.forename: Mariette
authors.initials: M
authors.lastname: Ackermans
authors.forename: Erik
authors.initials: E
authors.lastname: Endert
authors.forename: Mireille J
authors.initials: MJ
authors.lastname: Serlie
authors.forename: Peter
authors.initials: P
authors.lastname: Reiss
authors.forename: Hans P
authors.initials: HP
authors.lastname: Sauerwein
mesh_terms: D015502:Absorptiometry, Photon; D052242:Adiponectin / Q000096:biosynthesis*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D001823:Body Composition / Q000187:drug effects; D002153:Calorimetry, Indirect; D004311:Double-Blind Method; D005947:Glucose / Q000378:metabolism*; D015658:HIV Infections / Q000378:metabolism*; D015497:HIV-1; D039682:HIV-Associated Lipodystrophy Syndrome / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007333:Insulin Resistance / Q000502:physiology; D050356:Lipid Metabolism / Q000187:drug effects; D008066:Lipolysis / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D047495:PPAR gamma / Q000819:agonists; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*; D014057:Tomography, X-Ray Computed
chemical_list: D052242:Adiponectin; D007004:Hypoglycemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D005947:Glucose